 |
|
|
|
|
Oregon Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing OregonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Exelixis, Inc.
| Exelixis, Inc.
210 East Grand Avenue
PO Box 511
S. San Francisco, CA 94080-0511 |  |
| | | | Phone: | (650) 837-7000 | | Fax: | (650) 837-8300 | | Year Established: | 2000 | | Ticker: | EXEL | | Exchange: | NASDAQ | | Main Contact: | J. Scott Garland, Executive VP & CCO | | | | Other Contacts: | Andrew R. Peters, VP, Strategy
Gregg Bernier, VP of Marketing
William Berg, M.D., Senior VP, Medical Affairs
Gisela M. Schwab, MD, Executive VP & CMO
Jeffrey J. Hessekiel, J.D., Executive VP & General Counsel
Peter Lamb, Ph.D., Executive VP, Discovery Research & CSO
Chris Senner, Executive VP & CFO
Michael Morrissey, Ph.D,, President & CEO
Stefan Krauss, Ph.D., VP, Business Development
| | | | Company Description | | Exelixis is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, Sanofi-Aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. | |
|
|
|
|
|
|
|
